Premium
Application of epstein‐barr virus (EBV) serology to the diagnosis of north american nasopharyngeal carcinoma
Author(s) -
Pearson Gary R.,
Weiland Louis H.,
Neel H. Bryan,
Taylor William,
Earle John,
Mulroney Susan E.,
Goepfert Helmuth,
Lanier Anne,
Talvot Marion L.,
Pilch Ben,
Goodman Max,
Huang Andrew,
Levine Paul H.,
Hyams Vincent,
Moran Edgar,
Henle Gertrude,
Henle Werner
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830115)51:2<260::aid-cncr2820510216>3.0.co;2-#
Subject(s) - nasopharyngeal carcinoma , serology , medicine , occult , histopathology , virus , antibody titer , epstein–barr virus , antibody , cancer , disease , pathology , carcinoma , titer , immunology , alternative medicine , radiation therapy
A cooperative study was establishment among a number of institutions in the USA to determine the clinical value of Epstein‐Barr virus (EBV) serology for the diagnosis of different histopathological types of North American nasopharyngeal carcinoma (NPC) including occult primary tumors. One hundred‐twenty‐four patients with confirmed NPC have now been entered into the study. For each patient, anti‐EBV antibody titers were determined at diagnosis and related to the histopathology as classified according to the World Health Organization (WHO). The results suggest that certain anti‐EBV antibodies are of potential value for the diagnosis of undifferentiated types of NPC but not for the well‐differntiated cancer. The IgA anti‐VCA antibody response is the most specific for this disease and of the greatest diagnostic value when used alone or in combination with the anti‐EA test. These tests have also been used succesfully for the detection of occult NPC. These results indicate that these tests can be useful aids to the clinician for the diagnosis of certain histopathologic types of this disease.